This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today. 

The IRA requires drug companies to pay rebates to Medicare when prices for certain single-source and biosimilar prescription drugs covered under Part B increase faster than the rate of inflation. These 27 drugs are among the first rebatable drugs under the law. Part B drugs impacted by a coinsurance adjustment may change quarterly. For more information, see the CMS fact sheet.

Related News Articles

Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The AHA, joined by five other national hospital associations, Aug. 14 filed an amicus brief urging the Supreme Court to correct the Department of Health and…
Headline
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…
Headline
More than 46 million prior authorization requests were submitted to Medicare Advantage insurers in 2022, according to KFF analysis released Aug. 6 examining…
Headline
UnitedHealth Group Aug. 1 announced the creation of a gold card program for qualified practices. Under the program, the practices that earn gold card status…
Headline
A Commonwealth Fund report published Aug. 1 examines how frequently insured, working-age adults are denied care by insurers; how often they are billed for…